AI Article Synopsis
- The study evaluated the relationship between bleomycin (BLM)-induced apoptosis in peripheral blood mononuclear cells (PBMC) and survival rates in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
- A higher percentage of PBMC undergoing BLM-induced apoptosis, along with a greater rate of cycling PBMCs, were found to significantly correlate with increased patient survival time.
- Patients with both PBMC biomarkers above median values had median survival times of 60 months, compared to just 10 months for those with lower values, indicating these factors may serve as independent prognostic indicators before chemotherapy.
Article Abstract
The Bleomycin (BLM)-induced apoptosis in peripheral blood mononuclear cells (PBMC), from patients with advanced squamous cell carcinoma of the head and neck (SCCHN), cultured in vitro with PHA, was tested as a predictive indicator of the survival time. The rates of the PBMC BLM-induced apoptosis and of the cycling-PBMCs, measured respectively after Giemsa- and Feulgen-staining were determined in 25 patients before induction chemotherapy. By using the Cox model, the survival probability was significantly and independently increased for a high percentage of PBMC BLM-induced apoptosis and a high rate of cycling PBMCs. (Chi-2(2): 10; p=0.007). Six patients, in whom both PBMC variables were simultaneouly greater than the median values, showed a median survival time as long as 60 months versus 10 months for the other 19. Conclusively, the PBMC susceptibility to BLM-induced apoptosis as well as the PBMC capability for cycling may be regarded as independent pretherapeutic prognosis factors for patients with advanced SCCHN.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!